- Home
- SLMT vs ALGS Comparison
SLMT vs ALGS Comparison
Compare SLMT & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SLMT | ALGS |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.1M | 34.6M |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SLMT | ALGS |
|---|---|---|
| Price | $3.38 | $5.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $39.33 |
| AVG Volume (30 Days) | 52.1K | ★ 52.3K |
| Earning Date | 06-13-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,186,000.00 |
| Revenue This Year | N/A | $32.20 |
| Revenue Next Year | N/A | $4.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.56 | $3.98 |
| 52 Week High | $24.05 | $13.69 |
Technical Indicators
Market Signals| Indicator | SLMT | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 33.33 | 35.77 |
| Support Level | $0.79 | $4.80 |
| Resistance Level | $4.60 | $6.91 |
| Average True Range (ATR) | 0.32 | 0.53 |
| MACD | -0.06 | -0.22 |
| Stochastic Oscillator | 0.00 | 5.86 |
Price Performance
Historical ComparisonAbout SLMT Brera Holdings PLC Class B Ordinary Shares
Solmate Infrastructure Public Ltd is a Solana-based crypto infrastructure company with a strategic focus on Abu Dhabi. The group builds high-performance validators that lower latency, expand network reach, and position Abu Dhabi as a world-wide hub for Solana infrastructure. The company creates value by working with its partners to build infrastructure and real hardware for the crypto revolution. Its cutting-edge Solana staking infrastructure will help drive the adoption of the network in the Middle East.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.